Search

CN-122005387-A - New application of schizonepeta catarrhalis vesicles

CN122005387ACN 122005387 ACN122005387 ACN 122005387ACN-122005387-A

Abstract

The invention discloses a new application of schizonepeta cataria vesicles, which is realized by in vitro cells, and proves that the schizonepeta cataria vesicles can obviously reduce the expression of TNF-alpha and NF-kappa B inflammatory factors of macrophages, reduce the expression of TRPV1 of keratinocytes, increase the expression of LOR and FLG of keratinocytes, reduce the expression of SREBP-1 and ACC of sebaceous gland cells and promote the expression of Collagen III of fibroblasts, so that the schizonepeta cataria vesicles have obvious effects of relieving, repairing, controlling oil and tightening, and can be applied to skin care products with at least one of the effects of relieving, repairing, controlling oil and tightening.

Inventors

  • LI YUE
  • WU JIAYING
  • LI XIANG
  • ZHANG MENGYAO
  • CHEN DENGHUI
  • SHEN YIHAO
  • LIU MANMAN
  • HUANG HU

Assignees

  • 珀莱雅化妆品股份有限公司

Dates

Publication Date
20260512
Application Date
20260211

Claims (10)

  1. 1. Use of schizonepeta cataria vesicles for the preparation of a skin care product having at least one of soothing, repairing, controlling oil, tightening.
  2. 2. The method according to claim 1, wherein the product is a cosmetic or pharmaceutical product.
  3. 3. The method according to claim 1, wherein the method for extracting schizonepeta catarrhalis vesicles comprises the following steps: S1, crushing and pulping, namely adding a buffer solution into schizonepeta cataria, and crushing to prepare slurry; S2, enzymolysis, namely adding special enzyme for hydrolysis into the slurry, stirring and filtering to obtain filtrate; S3, separating, namely sequentially centrifuging the filtrate at low temperature at low speed, medium speed and high speed to obtain supernatant; S4, purifying, namely adding a high molecular precipitant into the supernatant, refrigerating, centrifuging, and re-suspending by using a buffer solution to obtain schizonepeta catarrhalis vesicles.
  4. 4. The method of claim 3, wherein in the step S1, the buffer solution is phosphate buffer solution, the preparation concentration of the phosphate buffer solution is 0.1-0.2 mol/L, and the feed liquid ratio of the slurry is (1:8) - (1:12) (W/V).
  5. 5. The method according to claim 3, wherein in the step S2, the addition amount of the enzyme special for hydrolysis is 0.1-0.5% of the raw material amount (W/W), the enzyme special for hydrolysis is composed of at least one of cellulase, pectase or hemicellulase, and the enzyme activity of the enzyme special for hydrolysis is not less than 300,000U/g.
  6. 6. The method of claim 3, wherein in the step S3, the low temperature is 2-6 ℃, the low-speed centrifugation is 800-1200 Xg, the medium-speed centrifugation is 2500-3500 Xg, the high-speed centrifugation is 9000-11000 Xg, and the centrifugation time is 10-30 min.
  7. 7. The method according to claim 3, wherein the centrifugation is performed under the conditions of 9000 to 12000 Xg for 10 to 20min in the step S4.
  8. 8. The method of claim 3, wherein in the step S4, the polymer precipitant is polyethylene glycol, and the addition amount of the polyethylene glycol is 8-12% (W/V) of the supernatant.
  9. 9. The method of claim 3, wherein in the step S4, the buffer solution is phosphate buffer solution, and the addition amount of the phosphate buffer solution is 0.25-1 times (V/W) of the raw material amount.
  10. 10. A cosmetic with soothing, repairing, oil controlling or tightening effects is characterized by comprising schizonepeta cataria vesicles.

Description

New application of schizonepeta catarrhalis vesicles Technical Field The invention relates to schizonepeta catarrhalis vesicles, in particular to a novel application of schizonepeta catarrhalis vesicles. Background The skin is the largest organ of the human body, plays an important role in barrier protection, and is the first barrier of the human body. In life, many factors such as climate change, working pressure, lifestyle and natural aging cause damage or aging of skin. Currently, the ingredients used in skin care cosmetics or external medicines are mainly plant extracts, fermentation products, monomers, and the like. However, these components have the problems of poor permeability, low transdermal rate, and difficult delivery during application, and are difficult to effectively exert their efficacy. Plant-derived vesicles (plant-DERIVED VESICLES, PDVLs) refer to all particles obtained from plants, plant tissues, which have a lipid bilayer membrane structure and are unable to replicate themselves. These particles may be uniformly dispersed in water. In terms of component composition, unlike the plant essential oil and the traditional plant extract which only contain a single component of secondary metabolites, the vesicle internally wraps a plurality of active components such as proteins, lipids, miRNAs, other secondary metabolites and the like, and the multicomponent synergistic action mode consisting of rich efficacy molecules has stronger application potential than the single component. In application, the lipid bilayer membrane structure provides natural biocompatibility advantages over traditional plant extracts. Compared with animal-derived vesicles, plant-derived vesicles have higher production efficiency, shorter extraction period, lower immunogenicity, and no ethical disputes. At present, the literature reports that the plant-derived vesicles have good application values in the aspects of anti-tumor, anti-inflammatory, intestinal homeostasis, wound regeneration, cell differentiation, tissue repair and the like. The plant-derived vesicles have wide application prospects in the field of skin care cosmetics or external medicines. Schizonepeta cataria Schizonepeta tenuifolia is a plant of the genus schizonepeta (Schizonepeta) of the family Labiatae (Lamiaceae). The Chinese plant Zhi states that the whole herb and the flower ears are common traditional Chinese medicines for treating symptoms such as wind-cold type common cold, headache, sore throat, skin itch and the like. Meanwhile, the whole grass is rich in aromatic oil, and the aromatic oil can be extracted. The prior publication CN118338892a, a novel composition comprising an exosome derived from nepeta as an active ingredient, discloses that exosomes obtained from fresh nepeta (NEPETA CATARIA, schizonepeta) or callus cell culture medium have the activity of improving skin elasticity, reducing skin wrinkles, and promoting wound healing. However, labiatae is one of the families with a large worldwide distribution, and has about 220 genera worldwide, including 3500 plants, and only China has more than 800 plants of 99 genera, and the plants of different genera objectively have inter-genus differences. Wherein, the schizonepeta and schizonepeta are divided into different genera, and the difference between the two genera is clear. At present, no related research on schizonepeta catarrhalis vesicles is seen, and the application of schizonepeta catarrhalis vesicles in the field of skin care is not clear. Disclosure of Invention The invention aims to provide a novel application of schizonepeta catarrhalis vesicles. The schizonepeta cataria vesicles can be used as functional components for relieving, repairing, controlling oil and compacting, and can be applied to skin care cosmetics or external pharmaceutical products. The technical scheme of the invention is as follows: Use of schizonepeta cataria vesicles for the preparation of a skin care product having at least one of soothing, repairing, controlling oil, tightening. In the foregoing application, the product is a cosmetic or pharmaceutical. In the foregoing application, the method for extracting schizonepeta catarrhalis vesicles comprises the following steps: S1, crushing and pulping, namely adding a buffer solution into schizonepeta cataria, and crushing to prepare slurry; S2, enzymolysis, namely adding special enzyme for hydrolysis into the slurry, stirring and filtering to obtain filtrate; S3, separating, namely sequentially centrifuging the filtrate at low temperature at low speed, medium speed and high speed to obtain supernatant; S4, purifying, namely adding a high molecular precipitant into the supernatant, refrigerating, centrifuging, and re-suspending by using a buffer solution to obtain schizonepeta catarrhalis vesicles. In the above application, in the step S1, the buffer solution is phosphate buffer solution, the concentration of the phosphate buffer solution is 0.1-0.2 mol/L, and the r